CO2023006731A2 - Composiciones y métodos para el tratamiento de la celiaquía - Google Patents
Composiciones y métodos para el tratamiento de la celiaquíaInfo
- Publication number
- CO2023006731A2 CO2023006731A2 CONC2023/0006731A CO2023006731A CO2023006731A2 CO 2023006731 A2 CO2023006731 A2 CO 2023006731A2 CO 2023006731 A CO2023006731 A CO 2023006731A CO 2023006731 A2 CO2023006731 A2 CO 2023006731A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- celiac disease
- compositions
- treatment
- celiac
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108163P | 2020-10-30 | 2020-10-30 | |
| PCT/US2021/057197 WO2022094177A1 (en) | 2020-10-30 | 2021-10-29 | Compositions and methods for treating celiac sprue disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023006731A2 true CO2023006731A2 (es) | 2023-06-09 |
Family
ID=78819631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0006731A CO2023006731A2 (es) | 2020-10-30 | 2023-05-24 | Composiciones y métodos para el tratamiento de la celiaquía |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250064903A1 (https=) |
| EP (1) | EP4237554A1 (https=) |
| JP (1) | JP2023548083A (https=) |
| KR (1) | KR20230093323A (https=) |
| CN (1) | CN116829166A (https=) |
| AR (1) | AR123961A1 (https=) |
| AU (1) | AU2021368118A1 (https=) |
| CA (1) | CA3195929A1 (https=) |
| CO (1) | CO2023006731A2 (https=) |
| MX (1) | MX2023004807A (https=) |
| TW (1) | TW202233834A (https=) |
| WO (1) | WO2022094177A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025068987A1 (en) | 2023-09-28 | 2025-04-03 | Takeda Pharmaceutical Company Limited | A method of producing a kumamolisin-as polypeptide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4475707B2 (ja) * | 1998-10-05 | 2010-06-09 | 武田薬品工業株式会社 | Ｎ末端メチオニンの除去方法 |
| CA2882502A1 (en) | 2011-08-10 | 2013-02-14 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating celiac sprue disease |
| US10266815B2 (en) * | 2013-08-14 | 2019-04-23 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating celiac sprue disease |
| NZ737500A (en) * | 2015-06-08 | 2025-02-28 | Univ Washington | Compositions and methods for treating celiac sprue disease |
| AU2017380106B2 (en) * | 2016-12-22 | 2024-05-09 | Ew Nutrition Gmbh | Stable protease variants |
-
2021
- 2021-10-29 MX MX2023004807A patent/MX2023004807A/es unknown
- 2021-10-29 AU AU2021368118A patent/AU2021368118A1/en active Pending
- 2021-10-29 CN CN202180068658.4A patent/CN116829166A/zh active Pending
- 2021-10-29 AR ARP210103015A patent/AR123961A1/es not_active Application Discontinuation
- 2021-10-29 EP EP21816227.9A patent/EP4237554A1/en not_active Withdrawn
- 2021-10-29 US US18/034,622 patent/US20250064903A1/en active Pending
- 2021-10-29 WO PCT/US2021/057197 patent/WO2022094177A1/en not_active Ceased
- 2021-10-29 KR KR1020237017895A patent/KR20230093323A/ko not_active Withdrawn
- 2021-10-29 JP JP2023525049A patent/JP2023548083A/ja active Pending
- 2021-10-29 TW TW110140404A patent/TW202233834A/zh unknown
- 2021-10-29 CA CA3195929A patent/CA3195929A1/en active Pending
-
2023
- 2023-05-24 CO CONC2023/0006731A patent/CO2023006731A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4237554A1 (en) | 2023-09-06 |
| AU2021368118A9 (en) | 2023-07-06 |
| CA3195929A1 (en) | 2022-05-05 |
| TW202233834A (zh) | 2022-09-01 |
| AR123961A1 (es) | 2023-01-25 |
| MX2023004807A (es) | 2023-05-10 |
| US20250064903A1 (en) | 2025-02-27 |
| AU2021368118A1 (en) | 2023-05-11 |
| JP2023548083A (ja) | 2023-11-15 |
| WO2022094177A1 (en) | 2022-05-05 |
| CN116829166A (zh) | 2023-09-29 |
| KR20230093323A (ko) | 2023-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000411A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| MX2020009514A (es) | Anticuerpos anti-claudina 18.2 (cldn18.2). | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
| CO2020009402A2 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
| DOP2022000229A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| BR112019000015A2 (pt) | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos | |
| MX392605B (es) | Compuestos, composiciones y metodos para el tratamiento de enfermedades. | |
| CL2022002963A1 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| BR112022004972A2 (pt) | Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso | |
| MX2020003095A (es) | Arni variante. | |
| BR112018014540A2 (pt) | formulações/composições compreendendo inibidor de btk | |
| BR112022004397A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos | |
| CO2022001977A2 (es) | Anticuerpos anti-cd96 y sus métodos de uso | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| BR112018013071A2 (pt) | uso de derivados de triptofano para formulações de proteínas | |
| CO2020013050A2 (es) | Enzimas quinureninasa humanas y sus usos | |
| BR112018010669A8 (pt) | anticorpo anti-pcsk9 e utilização do mesmo | |
| MX2023007228A (es) | Constructo de arn. | |
| MX2019000235A (es) | Eliminacion de la cistina mediada por enzimas humanas. | |
| MX2018005154A (es) | Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana. | |
| CO2023006731A2 (es) | Composiciones y métodos para el tratamiento de la celiaquía | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |